<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width,initial-scale=1" />
  <title>Cape Porpoise Clinical Consulting</title>
  <meta name="description" content="Clinical and regulatory consulting for early-stage biotech. Strategy to execution." />
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link href="https://fonts.googleapis.com/css2?family=Libre+Baskerville:ital,wght@0,400;0,700;1,400&family=DM+Sans:opsz,wght@9..40,400;9..40,500;9..40,600&display=swap" rel="stylesheet">

  <style>
    :root {
      --ink: #0e1219;
      --paper: #f7f4ef;
      --muted: #6b6660;
      --accent: #1a3a5c;
      --rule: #d4cfc7;
      --serif: 'Libre Baskerville', Georgia, serif;
      --sans: 'DM Sans', system-ui, sans-serif;
    }

    *, *::before, *::after { box-sizing: border-box; margin: 0; padding: 0; }
    html { scroll-behavior: smooth; }

    body {
      font-family: var(--sans);
      background: var(--paper);
      color: var(--ink);
      line-height: 1.6;
    }

    nav {
      position: sticky;
      top: 0;
      z-index: 100;
      background: rgba(247,244,239,.95);
      backdrop-filter: blur(10px);
      border-bottom: 1px solid var(--rule);
      padding: 0 48px;
      display: flex;
      justify-content: space-between;
      align-items: center;
      height: 64px;
    }

    .brand {
      display: flex;
      align-items: center;
      gap: 13px;
      text-decoration: none;
      color: var(--ink);
    }

    .brand-text { line-height: 1; }

    .brand-name {
      display: block;
      font-family: var(--serif);
      font-size: 13px;
      letter-spacing: .12em;
      text-transform: uppercase;
    }

    .brand-sub {
      display: block;
      font-size: 10px;
      letter-spacing: .07em;
      text-transform: uppercase;
      color: var(--muted);
      margin-top: 3px;
    }

    .nav-links { display: flex; gap: 28px; list-style: none; }

    .nav-links a {
      font-size: 12px;
      font-weight: 600;
      letter-spacing: .07em;
      text-transform: uppercase;
      color: var(--muted);
      text-decoration: none;
      transition: color .15s;
    }

    .nav-links a:hover { color: var(--ink); }

    .hero {
      min-height: 84vh;
      display: flex;
      flex-direction: column;
      justify-content: flex-end;
      padding: 72px 48px;
      border-bottom: 1px solid var(--rule);
    }

    .eyebrow {
      font-size: 11px;
      font-weight: 600;
      letter-spacing: .18em;
      text-transform: uppercase;
      color: var(--muted);
      margin-bottom: 22px;
      display: flex;
      align-items: center;
      gap: 12px;
      opacity: 0;
      animation: up .6s ease .1s forwards;
    }

    .eyebrow::before {
      content: '';
      width: 24px;
      height: 1px;
      background: var(--muted);
      flex-shrink: 0;
    }

    h1 {
      font-family: var(--serif);
      font-size: clamp(34px, 5.5vw, 72px);
      line-height: 1.08;
      letter-spacing: -.02em;
      max-width: 820px;
      margin-bottom: 32px;
      opacity: 0;
      animation: up .7s ease .2s forwards;
    }

    h1 em { font-style: italic; color: var(--accent); }

    .cta-row {
      display: flex;
      gap: 14px;
      align-items: center;
      opacity: 0;
      animation: up .7s ease .33s forwards;
    }

    .btn {
      background: var(--accent);
      color: #fff;
      padding: 13px 24px;
      border-radius: 3px;
      text-decoration: none;
      font-size: 13px;
      font-weight: 600;
      letter-spacing: .04em;
      transition: opacity .15s;
    }

    .btn:hover { opacity: .85; }

    .btn-link {
      font-size: 13px;
      color: var(--muted);
      text-decoration: none;
      font-weight: 500;
      transition: color .15s;
    }

    .btn-link:hover { color: var(--ink); }

    section { border-bottom: 1px solid var(--rule); }

    .row {
      max-width: 1060px;
      margin: 0 auto;
      padding: 72px 48px;
      display: grid;
      grid-template-columns: 180px 1fr;
      gap: 52px;
    }

    .label {
      font-size: 10.5px;
      font-weight: 700;
      letter-spacing: .18em;
      text-transform: uppercase;
      color: var(--muted);
      padding-top: 4px;
    }

    .focus-body p {
      font-size: 18px;
      line-height: 1.7;
      margin-bottom: 20px;
      max-width: 680px;
    }

    .focus-body p:last-child { margin-bottom: 0; }

    .tag-group { margin-bottom: 28px; }
    .tag-group:last-child { margin-bottom: 0; }

    .tag-group-title {
      font-size: 10.5px;
      font-weight: 700;
      letter-spacing: .16em;
      text-transform: uppercase;
      color: var(--muted);
      margin-bottom: 10px;
    }

    .tags { display: flex; flex-wrap: wrap; gap: 7px; }

    .tag {
      font-size: 13px;
      color: var(--ink);
      border: 1px solid var(--rule);
      padding: 5px 13px;
      border-radius: 999px;
      background: #fff;
    }

    .cred-intro {
      font-size: 18px;
      line-height: 1.7;
      max-width: 660px;
      margin-bottom: 40px;
    }

    .stats {
      display: grid;
      grid-template-columns: repeat(4, 1fr);
      gap: 1px;
      background: var(--rule);
      border: 1px solid var(--rule);
      border-radius: 5px;
      overflow: hidden;
    }

    .stat { background: var(--paper); padding: 24px 20px; }

    .stat strong {
      display: block;
      font-family: var(--serif);
      font-size: 38px;
      color: var(--accent);
      line-height: 1;
      margin-bottom: 6px;
    }

    .stat span { font-size: 12.5px; color: var(--muted); line-height: 1.4; }

    /* CHART */
    .chart-label {
      font-size: 10.5px;
      font-weight: 700;
      letter-spacing: .16em;
      text-transform: uppercase;
      color: var(--muted);
      margin-bottom: 16px;
    }

    .chart-bars {
      display: flex;
      align-items: flex-end;
      gap: 10px;
      height: 160px;
      border-bottom: 1px solid var(--rule);
      padding-bottom: 8px;
    }

    .chart-bar-wrap {
      display: flex;
      flex-direction: column;
      align-items: center;
      gap: 6px;
      flex: 1;
    }

    .chart-bar {
      width: 100%;
      background: var(--accent);
      border-radius: 2px 2px 0 0;
    }

    .chart-bar-label {
      font-size: 11px;
      color: var(--muted);
      text-align: center;
      line-height: 1.4;
    }

    .chart-bar-label strong { color: var(--ink); display: block; }

    .chart-source {
      font-size: 12px;
      color: var(--muted);
      margin-top: 16px;
      max-width: 560px;
      line-height: 1.55;
    }

    .svc-cols {
      display: grid;
      grid-template-columns: 1fr 1fr;
      gap: 1px;
      background: var(--rule);
      border: 1px solid var(--rule);
      border-radius: 5px;
      overflow: hidden;
      width: 100%;
    }

    .svc-col { background: var(--paper); padding: 32px 28px; }

    .svc-col-label {
      font-size: 10px;
      font-weight: 700;
      letter-spacing: .17em;
      text-transform: uppercase;
      color: var(--muted);
      margin-bottom: 5px;
    }

    .svc-col-title {
      font-family: var(--serif);
      font-size: 19px;
      line-height: 1.2;
      margin-bottom: 7px;
    }

    .svc-desc {
      font-size: 13.5px;
      color: var(--muted);
      line-height: 1.55;
      margin-bottom: 20px;
      padding-bottom: 20px;
      border-bottom: 1px solid var(--rule);
    }

    .svc-list { list-style: none; display: flex; flex-direction: column; gap: 10px; }

    .svc-list li {
      font-size: 14px;
      color: var(--muted);
      line-height: 1.45;
      padding-left: 14px;
      position: relative;
    }

    .svc-list li::before {
      content: '';
      position: absolute;
      left: 0;
      top: 9px;
      width: 5px;
      height: 1px;
      background: var(--rule);
    }

    .about-body p {
      font-size: 15.5px;
      line-height: 1.78;
      color: var(--muted);
      margin-bottom: 16px;
      max-width: 660px;
    }

    .about-body p:last-child { margin-bottom: 0; }
    .about-body strong { color: var(--ink); font-weight: 600; }

    .about-body a {
      color: var(--accent);
      text-decoration: none;
      border-bottom: 1px solid var(--rule);
      transition: border-color .15s;
    }

    .about-body a:hover { border-color: var(--accent); }

    .contact-tag {
      font-family: var(--serif);
      font-size: 25px;
      line-height: 1.3;
      margin-bottom: 28px;
      max-width: 440px;
    }

    .contact-links { display: flex; flex-direction: column; margin-bottom: 24px; }

    .contact-link {
      display: flex;
      justify-content: space-between;
      align-items: center;
      font-size: 16px;
      font-weight: 500;
      color: var(--accent);
      text-decoration: none;
      padding: 13px 0;
      border-bottom: 1px solid var(--rule);
      transition: color .15s;
    }

    .contact-link:first-child { border-top: 1px solid var(--rule); }
    .contact-link:hover { color: #2d5f8a; }

    .arr { transition: transform .15s; }
    .contact-link:hover .arr { transform: translateX(4px); }

    .contact-note { font-size: 13px; color: var(--muted); line-height: 1.65; max-width: 380px; }

    footer {
      padding: 22px 48px;
      display: flex;
      justify-content: space-between;
      flex-wrap: wrap;
      gap: 8px;
    }

    footer p { font-size: 12px; color: var(--muted); }

    @keyframes up {
      from { opacity: 0; transform: translateY(20px); }
      to   { opacity: 1; transform: translateY(0); }
    }

    @media (max-width: 780px) {
      nav { padding: 0 20px; }
      .nav-links { display: none; }
      .brand-sub { display: none; }
      .hero { padding: 56px 20px; min-height: 68vh; }
      .row { grid-template-columns: 1fr; gap: 14px; padding: 52px 20px; }
      .svc-cols { grid-template-columns: 1fr; }
      .stats { grid-template-columns: 1fr 1fr; }
      footer { padding: 18px 20px; }
    }
  </style>
</head>

<body>

  <nav>
    <a class="brand" href="#top">
      <div class="brand-text">
        <span class="brand-name">CPCC</span>
        <span class="brand-sub">Cape Porpoise Clinical Consulting</span>
      </div>
    </a>
    <ul class="nav-links">
      <li><a href="#focus">Focus</a></li>
      <li><a href="#why-now">Why Now</a></li>
      <li><a href="#expertise">Expertise</a></li>
      <li><a href="#services">Services</a></li>
      <li><a href="#about">About</a></li>
      <li><a href="#contact">Contact</a></li>
    </ul>
  </nav>

  <div class="hero" id="top">
    <div class="eyebrow">Cape Porpoise Clinical Consulting &middot; Cambridge, MA</div>
    <h1>For Clinical-stage biotechs<br>charting a path to the <em>  first clinical inflection point.</em></h1>
    <div class="cta-row">
      <a class="btn" href="#contact">Get in touch</a>
    </div>
  </div>

  <section id="focus">
    <div class="row">
      <div class="label">What we do</div>
      <div class="focus-body">
        <p>CPCC works exclusively with <strong>early clinical-stage biotech companies</strong> to navigate the path from program initiation to the first meaningful clinical inflection point: the data, regulatory decisions, and milestones that unlock the next chapter.</p>
        <p>Whether you need a senior thought partner at the investor or FDA table, or someone to build the documents and run the work, CPCC covers the full range. High-level development strategy through hands-on execution and submission-ready deliverables.</p>
      </div>
    </div>
  </section>

  <section id="why-now">
    <div class="row">
      <div class="label">Why Now</div>
      <div>
        <p style="font-size:18px;line-height:1.7;max-width:660px;margin-bottom:36px;">
          In today's market, <strong>clinical data is the currency of biotech value creation.</strong> Partnerships, M&amp;A, and financing rounds increasingly hinge on clean early readouts — not pipeline potential alone. Large pharma, facing patent cliffs and depleted pipelines, is actively hunting for clinical-stage assets with de-risked data packages. In 2022–24, a higher proportion of biopharma deals focused on assets already in clinical development, reversing a prior trend toward earlier-stage innovation. Getting to that first inflection point, efficiently and credibly, is what creates optionality.
        </p>

        <div class="chart-label">Biopharma deal value by year (USD billions) &mdash; LSEG / IQVIA / McKinsey</div>
        <div class="chart-bars">
          <div class="chart-bar-wrap">
            <div class="chart-bar" style="height:52px;opacity:.7;"></div>
            <div class="chart-bar-label">2020<strong>$98B</strong></div>
          </div>
          <div class="chart-bar-wrap">
            <div class="chart-bar" style="height:130px;opacity:.8;"></div>
            <div class="chart-bar-label">2021<strong>$189B</strong></div>
          </div>
          <div class="chart-bar-wrap">
            <div class="chart-bar" style="height:42px;opacity:.7;"></div>
            <div class="chart-bar-label">2022<strong>$84B</strong></div>
          </div>
          <div class="chart-bar-wrap">
            <div class="chart-bar" style="height:160px;"></div>
            <div class="chart-bar-label">2023<strong>$244B</strong></div>
          </div>
          <div class="chart-bar-wrap">
            <div class="chart-bar" style="height:112px;opacity:.85;"></div>
            <div class="chart-bar-label">2024<strong>$191B</strong></div>
          </div>
        </div>
        <p class="chart-source">Sources: LSEG, IQVIA, McKinsey. Deal values reflect biopharma acquisitions of majority stakes exceeding $1B. 2023 marked the highest aggregate deal value since 2019. From 2022 onward, dealmaking has shifted decisively toward clinical-stage assets with existing data packages.</p>
      </div>
    </div>
  </section>

  <section id="expertise">
    <div class="row">
      <div class="label">Expertise</div>
      <div>
        <div class="tag-group">
          <div class="tag-group-title">Therapeutic Areas</div>
          <div class="tags">
            <span class="tag">Cardiovascular</span>
            <span class="tag">Neurology</span>
            <span class="tag">Rare Disease</span>
            <span class="tag">Oncology</span>
            <span class="tag">Pain</span>
            <span class="tag">Microbiome / GI</span>
          </div>
        </div>
        <div class="tag-group">
          <div class="tag-group-title">Modalities</div>
          <div class="tags">
            <span class="tag">Antibody Fusions</span>
            <span class="tag">Antibody-Drug Conjugates</span>
            <span class="tag">Bispecific Antibodies</span>
            <span class="tag">RNAi / siRNA</span>
            <span class="tag">Small Molecules</span>
            <span class="tag">Inhaled Drug Delivery</span>
            <span class="tag">Microbiome Therapeutics</span>
          </div>
        </div>
        <div class="tag-group">
          <div class="tag-group-title">Companies</div>
          <div class="tags">
            <span class="tag">Salubris Biotherapeutics</span>
            <span class="tag">Acorda Therapeutics</span>
            <span class="tag">Dicerna Pharmaceuticals</span>
            <span class="tag">Nocion Therapeutics</span>
            <span class="tag">Elevian</span>
            <span class="tag">Finch Therapeutics</span>
            <span class="tag">Pharmica Consulting</span>
          </div>
        </div>
      </div>
    </div>
  </section>

  <section id="credentials">
    <div class="row">
      <div class="label">Track Record</div>
      <div>
        <p class="cred-intro">Over 16 years inside small and midsize biotech across Boston and Cambridge, Amanda has guided programs from first-in-human through FDA approval, exits, and partnerships. Two FDA-approved drugs. Twelve INDs. Three NDA contributions. Therapeutic areas spanning cardiovascular, neurology, rare disease, oncology, and pain across a wide range of modalities.</p>
        <div class="stats">
          <div class="stat"><strong>16+</strong><span>Years in clinical biotech leadership</span></div>
          <div class="stat"><strong>12+</strong><span>INDs filed</span></div>
          <div class="stat"><strong>3</strong><span>NDA contributions</span></div>
          <div class="stat"><strong>2</strong><span>FDA-approved therapies</span></div>
        </div>
      </div>
    </div>
  </section>

  <section id="services">
    <div class="row">
      <div class="label">Services</div>
      <div class="svc-cols">
        <div class="svc-col">
          <div class="svc-col-label">Strategic</div>
          <div class="svc-col-title">Advisory and Consulting</div>
          <p class="svc-desc">Senior judgment at the table for investor and regulatory interactions and program-level planning.</p>
          <ul class="svc-list">
            <li>Clinical and regulatory development plans</li>
            <li>Trial design and endpoint strategy</li>
            <li>FDA meeting preparation and participation</li>
            <li>Investor and board-level scientific advisory</li>
            <li>Regulatory pathway and risk assessment</li>
            <li>Partnership and due diligence support</li>
          </ul>
        </div>
        <div class="svc-col">
          <div class="svc-col-label">Execution</div>
          <div class="svc-col-title">Clinical and Regulatory Work</div>
          <p class="svc-desc">Submission-ready deliverables built directly. First drafts that hold up through review.</p>
          <ul class="svc-list">
            <li>Medical writing: IBs, protocols, ICFs, CSRs</li>
            <li>IND and CTA preparation and submission</li>
            <li>Regulatory correspondence and agency responses</li>
            <li>Clinical trial project management</li>
            <li>Vendor oversight and operational problem-solving</li>
            <li>QC and narrative coherence review</li>
          </ul>
        </div>
      </div>
    </div>
  </section>

  <section id="about">
    <div class="row">
      <div class="label">About</div>
      <div class="about-body">
        <p>CPCC is led by <strong>Amanda McEwen</strong> — <a href="https://www.linkedin.com/in/amandamariegentilemcewen/" target="_blank" rel="noopener">LinkedIn</a> — SVP of Clinical Development at Salubris Biotherapeutics, where she leads the JK07 program, a first-in-class ErbB4 agonist in Phase 2b for heart failure.</p>
        <p>Amanda has spent more than 16 years inside small to midsize biotech teams in Boston and Cambridge, running programs from first-in-human through FDA-approved therapies, including <strong>Inbrija</strong> (inhaled levodopa for Parkinson's OFF episodes, approved 2018) and <strong>Rivfloza</strong> (for primary hyperoxaluria type 1). Her work spans antibody fusions, ADCs, RNAi, inhaled delivery, small molecules, and microbiome therapeutics across neurology, cardiovascular, rare disease, oncology, pain, and GI.</p>
        <p>She is an <strong>Executive Fellow at Harvard Business School</strong> in entrepreneurship and life sciences, and <strong>adjunct faculty at Northeastern University</strong> in the MS in Regulatory Affairs program.</p>
      </div>
    </div>
  </section>

  <section id="contact">
    <div class="row">
      <div class="label">Contact</div>
      <div>
        <p class="contact-tag">Let's talk about where your program is and what it needs to get to the next inflection point.</p>
        <div class="contact-links">
          <a class="contact-link" href="mailto:amanda.gentile@gmail.com">amanda.gentile@gmail.com <span class="arr">&#8594;</span></a>
          <a class="contact-link" href="tel:+16176459160">617 645 9160 <span class="arr">&#8594;</span></a>
        </div>
        <p class="contact-note">First call covers program stage, near-term goals, key deliverables, and timeline. A simple statement of work follows. No long procurement cycles.</p>
      </div>
    </div>
  </section>

  <footer>
    <p>&#169; <span id="y"></span> Cape Porpoise Clinical Consulting</p>
    <p>Cambridge, Massachusetts</p>
  </footer>

  <script>document.getElementById("y").textContent = new Date().getFullYear();</script>
</body>
</html>
